Cytos Biotechnology AG / Key word(s): Half Year Results
30.09.2014 07:00

Release of an ad hoc announcement pursuant to Art. 53 KR

---

Schlieren (Zurich), Switzerland, September 30, 2014 - Cytos Biotechnology Ltd. (SIX:CYTN) ("Cytos" or the "Company") announced today its financial results for the first half year ended June 30, 2014.
Financial Results

Six-month period from January 1 to June 30, 2014

Funds available for financing the Company's operations amount to CHF 18.69 million as per June 30, 2014, and include cash and cash equivalents, financial assets and trade and other receivables. This is CHF 21.31 million lower than on December 31, 2013 (CHF 40.00 million). Cash decreased primarily due to expenses incurred from ongoing operating activities (CHF 13.71 million) as well as funds spent on wind-down agreements with suppliers (CHF 5.60 million). In addition, as a result of a settlement agreement, a payment of CHF 2.00 million was made in the second quarter of 2014. On June 30, 2014, the nominal value of convertible bonds not held by the Company amounted to CHF 13.17 million. Cytos did not buy back any convertible bonds on the market during the first half year of 2014.
Revenue comprising deferred income from license fees paid by Novartis of CHF 0.50 million has been recognized in the first six month of 2014, unchanged from the same period in 2013.

Financial summary (IFRS, consolidated)


The detailed First Half Year Financial Report 2014 can be downloaded at:
http://www.cytos.com/uploads/2014/Cytos_HY_1_2014_EN.pdf
For further information, please contact: 

Cytos Biotechnology Ltd 
Harry Welten, MBA 
Chief Financial Officer 
Tel: +41 44 733 46 46 
harry.welten@cytos.com 

About Cytos Biotechnology Ltd 

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements 
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com
 



+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=TAFKSMTJHO Document title: Cytos_HY1_2014_EN


30.09.2014 News transmitted by EQS Schweiz AG. 
The issuer is responsible for the contents of the release.
EQS publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1'300 listed companies. 
The Swiss news archive can be found at www.equitystory.ch/news

---

 
Language:               English
Company:                Cytos Biotechnology AG
                        Wagistr. 25
                        8952 Schlieren
                        Switzerland
Phone:                  +41 44 733 4747
Fax:                    +41 44 733 4740
E-mail:                 info@cytos.com
Internet:               www.cytos.com
ISIN: CH0011025217, CH0029060735 Valor:                  -
Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX  
End of Announcement EQS Group News-Service  

---